Knowledge Topic

How to Validate and Monitor Manufacturing Agent Performance Over Time

Manufacturing AI agent monitoring helps teams confirm that an agent continues to use approved data, follow its intended scope, produce traceable evidence, and escalate problems correctly after deployment.

Industry context

A manufacturing routine that runs once per shift produces 1,095 outputs per year. If a prelaunch test covers only 50 outputs, it evaluates less than 5% of that first-year volume.

At a glance

Validating a manufacturing AI agent is not a one-time test performed before launch. An agent may run for months while its source data, asset mappings, user roles, controlled documents, prompts, models, and operating conditions change.

A sound validation program begins with a clear intended-use statement. It defines what the agent may do, which users and systems it may serve, what evidence it must provide, which conditions require escalation, and which decisions remain with qualified people. Teams then establish baseline tests for normal cases, unusual conditions, restricted access, stale data, conflicting records, missing evidence, failed schedules, audit events, and human-review boundaries.

After deployment, monitoring should cover more than answer accuracy. Useful measures include evidence completeness, source freshness, reviewer disagreement, override frequency, access failures, scope errors, unresolved exceptions, escalation time, and failed or delayed routine execution.

Material changes should trigger an impact assessment. A new data source, model, prompt, historian tag, document version, permission rule, or workflow action may require targeted testing or full revalidation.

The goal is not to prove that an agent can never fail. The goal is to identify failures quickly, contain affected workflows, preserve evidence, correct the cause, and confirm that the correction works before routine operation resumes.

On this page

Overview

That simple calculation explains why validation cannot stop at go-live. The NIST AI Risk Management Framework Playbook recommends lifecycle monitoring, documented performance measurement, incident response, and continual improvement rather than relying only on an initial assessment (National Institute of Standards and Technology, 2023).

A manufacturing agent may continue to produce technically fluent answers while its operating context changes. A table may be renamed. A historian tag may be reassigned. A controlled procedure may be replaced. A reviewer may move to another role. A model or prompt update may change how the agent explains uncertainty.

The right operating model is therefore a continuous cycle:

Define → Test → Baseline → Monitor → Investigate → Correct → Revalidate

This cycle applies whether the agent supports quality triage, maintenance review, downtime analysis, yield investigation, root cause analysis, or another bounded manufacturing workflow.

Three reasons agent performance can decline after deployment

A successful pilot does not prove repeatable operation

Pilots usually involve known questions, cooperative users, stable systems, and carefully selected examples. Live manufacturing introduces unusual products, missing records, inconsistent timestamps, source outages, revised procedures, role changes, and questions that fall outside the original design.

An agent that answered a demonstration question correctly may fail when the same question is asked for another plant, product family, or time zone. It may also retrieve the right type of record from the wrong asset or use an obsolete document because the document repository was not updated correctly.

Validation must therefore test the complete workflow. That includes identity, permissions, source selection, scope resolution, evidence presentation, escalation, scheduling, audit records, pause controls, and human review.

The U.S. Food and Drug Administration’s 2026 draft guidance on Computer Software Assurance describes a risk-based approach for establishing confidence in production and quality management system software. Although a manufacturing agent may fall outside the specific scope of that guidance, its intended-use and risk-based testing principles provide a useful model for regulated implementations (U.S. Food and Drug Administration, 2026).

Answer accuracy is only one part of safe performance

An answer can be factually plausible and still be unusable.

The agent may have selected the wrong line, hidden a source conflict, included a restricted field, used stale data, or failed to route the output to the person responsible for review. A simple accuracy score will not reveal all of those failures.

A balanced monitoring program should evaluate:

Scope accuracy: Did the workflow use the correct site, line, asset, product, lot, and time window?

Evidence completeness: Can the reviewer open the records supporting each important claim?

Source freshness: Were current records and effective document versions used?

Access compliance: Did the user receive only the data permitted for that role?

Escalation performance: Did the agent stop or route work when evidence was incomplete?

Human-review quality: Did the reviewer accept, correct, reject, or escalate the output?

Operational reliability: Did scheduled routines run at the correct time and deliver results to the right queue?

ISO/IEC 42001:2023 places AI inside a management-system discipline that includes policies, objectives, performance evaluation, monitoring, and continual improvement. That structure is useful because it treats agent monitoring as an organizational process, not only a technical dashboard (International Organization for Standardization, 2023).

Drift can occur outside the model

Teams often think of drift as a change in model behavior. Manufacturing agents can also experience source, workflow, access, and context drift.

A new asset may inherit the wrong metadata. A supplier code may change. A procedure may be superseded but remain searchable. A user may retain access after changing jobs. A saved routine may continue using an old threshold after the process owner updates the operating limit.

These failures may not create an obvious system error. The agent may continue to produce a polished response based on the wrong context.

ISO/IEC 23894:2023 provides guidance for integrating AI risk management into organizational activities. Its risk-management approach supports regular reassessment when the system, context, users, data, or consequences of failure change (International Organization for Standardization, 2023).

Ask this → Get that

Ask This → Get That: A manufacturing agent validation walkthrough

Ask this

“What is this agent intended to do?”

Get

A testable performance contract.

The intended-use statement should identify the workflow, users, systems, records, permitted outputs, prohibited actions, human-review point, owner, and stop conditions. It should also define what acceptable performance means.

A useful statement might read:

Retrieve production, maintenance, historian, and approved procedure evidence related to an equipment excursion, then prepare a non-binding evidence summary for a qualified reviewer.

“Support maintenance” is too broad. The narrower statement gives the team something it can validate and monitor.

Ask this

“Which test cases prove that it works?”

Get

A version-controlled baseline test set.

Include normal questions and difficult conditions. Test unavailable sources, stale documents, incorrect plant scope, missing mappings, conflicting timestamps, restricted fields, delayed schedules, unexpected terminology, and out-of-scope requests.

Each test record should include:

Test objective
Input question or event
User role
Data and document versions
Expected result
Actual result
Evidence captured
Pass or fail decision
Defect owner
Required retest

The baseline should include examples that the agent must decline or escalate. A system that always attempts an answer has not demonstrated safe failure.

Ask this

“What happens when the agent cannot be trusted?”

Get

Tested containment behavior.

Inject faults deliberately. Map a historian signal to the wrong asset in a test environment. Remove a required source. Present two records with conflicting timestamps. Attempt retrieval as a restricted user. Replace a current procedure with an expired version.

The agent should disclose the problem, block prohibited access, avoid unsupported conclusions, preserve the event, and route the issue to the correct owner.

The OWASP Top 10 for Agentic Applications 2026 identifies risks such as goal hijacking, tool misuse, identity and privilege abuse, memory poisoning, cascading failures, and rogue-agent behavior. These risks reinforce the need to test the controls around the agent, not only the language produced at the end (OWASP Foundation, 2025).

Ask this

“How will we know performance is changing?”

Get

A monitoring scorecard with thresholds and owners.

Useful measures include:

Percentage of outputs with complete evidence
Percentage using current source records
Reviewer correction and rejection rate
Human override rate
Out-of-scope stop rate
Access-control failure rate
Escalation completion time
Failed or late routine runs
Source disagreement rate
Unresolved exception count
Changes waiting for impact assessment
Time from defect detection to containment

Do not display metrics without thresholds. Define the warning level, investigation level, and stop level before deployment.

For example, one missing optional source may produce a warning. Failure to verify an asset mapping may require the routine to stop. Unauthorized data exposure should trigger immediate containment and security review.

Ask this

“Which outputs should humans inspect?”

Get

A risk-based review queue.

Review every critical exception. Also sample normal outputs because gradual performance decline may not appear in the exception queue.

Reviewers should check the question, scope, sources, evidence, uncertainty, recommendation, and final disposition. Their corrections should become input for future tests and training.

The monitoring process should distinguish between an agent problem and an environment problem. A wrong answer may result from the model, retrieval logic, source data, access configuration, asset mapping, document governance, or unclear intended use.

Ask this

“Does this change require revalidation?”

Get

A documented impact decision.

Changes that may trigger testing include:

New or replaced AI model
Prompt or orchestration update
Added data source
Schema or historian-tag change
Modified asset mapping
New product or process family
Revised controlled document
Role or permission change
Changed escalation threshold
New workflow action
New deployment environment

The decision may be no retest, targeted regression testing, partial revalidation, full revalidation, or temporary suspension. Record the decision and its rationale.

MITRE ATLAS can also support security-focused reassessment because it provides a living knowledge base of adversarial tactics and techniques affecting AI-enabled systems (MITRE, current).

Illustrative example

Example Case Study – How the Solution Benefits

This is an illustrative example.

Problem: A quality evidence routine ran three times per day. Eight percent of its outputs required a reviewer to reconstruct missing source evidence, and each reconstruction took about 30 minutes.

Approach: The team introduced evidence-completeness gates, source-freshness checks, a warning for conflicting records, weekly output sampling, and a rule that paused the routine after a failed critical mapping test. It also assigned owners for data, workflow, access, validation, and business review.

Result: The reconstruction rate fell from 8% to 2%. Across 1,095 annual runs, avoidable review work declined from about 44 hours to 11 hours, returning approximately 33 expert hours per year. More importantly, reviewers no longer discovered missing evidence after relying on an output.

The useful metric was not “the agent is 98% accurate.” The stronger result was that the organization could identify defects, contain affected routines, trace impacted outputs, correct the cause, and document reactivation.

Common questions

Frequently asked questions

How often should a manufacturing AI agent be revalidated?

Use a risk-based schedule and perform an impact assessment after every material change. High-impact workflows may need frequent sampling and periodic formal review, while low-risk information workflows may justify a lighter schedule. Source, model, permission, mapping, intended-use, escalation, or human-review changes should always be assessed.

What is the most important agent performance metric?

There is no single sufficient metric. Begin with critical control failures such as unauthorized access, missing evidence, incorrect scope, failed escalation, or inability to stop the routine. Then monitor accuracy, completeness, reviewer action, source quality, operational reliability, and time to containment.

Next step

Manufacturing Agent Validation and Monitoring Checklist

Use a Manufacturing Agent Validation and Monitoring Checklist to document intended use, baseline tests, monitoring thresholds, drift indicators, change-control triggers, containment actions, and revalidation evidence.

To apply this framework to a bounded plant workflow, explore the Connected Manufacturing 90-Day Design Partner Program.

Sources

References

International Organization for Standardization. (2023). ISO/IEC 23894:2023, Artificial intelligence: Guidance on risk management.
This standard provides guidance for identifying and managing risks related to AI systems, products, and services. ISO is an international standards organization whose publications are developed through formal expert and consensus processes. The source supports the article’s recommendations for risk-based monitoring, change assessment, and periodic reassessment of agent context.
International Organization for Standardization. (2023). ISO/IEC 42001:2023, Information technology: Artificial intelligence management system.
This standard defines requirements for establishing, implementing, maintaining, and continually improving an AI management system. ISO/IEC 42001 is authoritative because it is the international management-system standard focused specifically on organizational AI governance. It supports the article’s treatment of monitoring, performance evaluation, ownership, corrective action, and continual improvement as management responsibilities.
MITRE. (Current). MITRE ATLAS.
MITRE ATLAS is a living knowledge base of adversarial tactics and techniques affecting AI-enabled systems. MITRE is a not-for-profit organization that operates federally funded research and development centers and produces widely used cybersecurity knowledge bases. The resource supports security testing, threat-informed monitoring, and reassessment of manufacturing agents when new adversarial techniques emerge.
National Institute of Standards and Technology. (2023). NIST AI Risk Management Framework Playbook.
The Playbook provides suggested actions aligned with the Govern, Map, Measure, and Manage functions of the NIST AI Risk Management Framework. NIST is a United States government standards and measurement agency, making the Playbook an authoritative cross-industry risk-management resource. It supports the article’s recommendations for lifecycle monitoring, performance thresholds, incident response, safe failure, recovery, and documented improvement.
OWASP Foundation. (2025). OWASP Top 10 for Agentic Applications for 2026.
This resource identifies major security risks associated with AI agents that plan, use tools, access information, and execute multistep workflows. OWASP is a nonprofit, community-led software security organization whose guidance is developed through open expert collaboration. The source supports the article’s recommendation to test identity, privileges, tools, memory, workflow boundaries, cascading failure, and agent containment.
U.S. Food and Drug Administration. (2026). Computer Software Assurance for Production and Quality Management System Software, draft guidance.
This draft guidance describes a risk-based approach for establishing confidence in software used in medical-device production and quality management systems. FDA is the United States regulator responsible for medical-device requirements and related industry guidance. The source supports the article’s emphasis on intended use, proportional testing, objective evidence, critical thinking, and assurance effort based on potential risk.